Raltitrexed is a quinazoline folate analogue with antineoplastic activity. After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)
Raltitrexed is a folate analogue antifolate agent synthesized via advanced catalytic processes. It functions as a specific thymidylate synthase inhibitor, preventing DNA synthesis in rapidly dividing cells. Its molecular formula is C24H26N6O7S, and the CAS registry number is 109615-68-7.
Strictly contraindicated in patients with severe renal impairment or hypersensitivity to the compound. Storage requires controlled temperatures between 2°C and 8°C in dry, light-resistant containers. Personnel must utilize appropriate PPE during handling to prevent dermal exposure and inhalation risks.